Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    LivaNova

    NASDAQ: LIVN · Real-Time Price · USD
    46.13
    0.05 (0.11%)
    At close: Jul 03, 2025, 1:10 PM
    45.72
    -0.89%
    After-hours: Jul 03, 2025, 04:08 PM EDT
    0.11%
    Bid 45.72
    Market Cap 2.52B
    Revenue (ttm) 1.28B
    Net Income (ttm) -222.15M
    EPS (ttm) -4.07
    PE Ratio (ttm) -11.33
    Forward PE 11.73
    Analyst Buy
    Ask 46.22
    Volume 243,250
    Avg. Volume (20D) 776,883
    Open 46.41
    Previous Close 46.08
    Day's Range 45.89 - 46.49
    52-Week Range 32.48 - 57.35
    Beta 0.91

    About LIVN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol LIVN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for LIVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    LivaNova is scheduled to release its earnings on Jul 30, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +23.72%
    LivaNova shares are trading higher after the compa... Unlock content with Pro Subscription
    3 months ago
    +5.53%
    LivaNova shares are trading higher. Needham reiterated a Buy rating on the stock.
    news image

    1 month ago · businesswire.com

    CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

    LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced completion of the CORE-VNS study further validating effectiveness of VNS Therapy for severe focal seizures in children & adults.

    news image

    1 month ago · businesswire.com

    LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

    LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced CORE-VNS 24-month data show adjunctive VNS Therapy associated with substantial reduction in generalized tonic-clonic seizures.

    news image

    1 month ago · businesswire.com

    LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

    LONDON--(BUSINESS WIRE)-- #depression--LivaNova PLC announced it initiated the process with U.S. CMS to seek reconsideration of national Medicare coverage for VNS Therapy in depression.

    news image

    1 month ago · businesswire.com

    LivaNova to Present at the Jefferies Global Healthcare Conference

    LONDON--(BUSINESS WIRE)-- #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside c...

    news image

    1 month ago · seekingalpha.com

    LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript

    LivaNova PLC (NASDAQ:LIVN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Briana Gotlin – Vice President, Investor Relations Vladimir Makatsaria – Chief Executive Office...

    news image

    1 month ago · zacks.com

    LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates

    LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago.

    news image

    1 month ago · businesswire.com

    LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

    LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-...

    news image

    1 month ago · businesswire.com

    LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

    LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), ev...

    Add to Watchlist